Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

Cepheid Announces World Health Organization Prequalification of Xpert HIV-1 Qualitative Test By Investing.com

Shooter Detection Systems to Showcase the Latest in Gunshot Detection Innovations at ISC West 2024 By Investing.com

[the_ad id="21475"]

[ad_1]

Point of Care HIV diagnostic testing for infants and early detection of HIV infections  

SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ — Cepheid today announced that Xpert ® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification list signifies that Xpert HIV-1 Qual XC meets WHO‘s stringent performance, quality, safety and reliability standards. Xpert HIV-1 Qual XC (extended coverage) is an in vitro nucleic acid amplification test for the qualitative detection of HIV-1 total nucleic acids directly from human dried blood spots and capillary or venous whole blood specimens.

 

Xpert HIV-1 Qual XC provides extended strain coverage by including two gene targets for the identification of HIV-1 infections – delivering results up to seven to ten days before seroconversion. The test has been cleared for use in early diagnosis of infants, adolescents, and adults at the point of care and in laboratories.

Prompt diagnosis and treatment are critical for survival of infants with HIV. Untreated, around 50% of infants infected with HIV during or around the time of birth will die before the age of two years.1  Although efforts have been made to scale up diagnosis, only around 60% of exposed infants are given an HIV test within the first two months of life.1  

“Timing is critical for infants born to mothers living with HIV. When accurate and sensitive test results are provided to clinicians quickly, they can immediately initiate the highly effective therapies that are now available to babies with HIV.” said  Devasena  Gnanashanmugam,  M.D. and VP Medical Affairs at Cepheid. “Mothers and families also benefit from the test’s quick turnaround time since they have fewer days of anxiety waiting for answers.”  

In high-burden regions, centralized laboratory-based infant diagnosis often results in only about half of infants and children living with HIV being linked to and initiated on antiretroviral therapy (ART). Simple point-of-care molecular tests can deliver results to the care giver on the same day, enable earlier linkage to care and initiation of ART, and improve retention in care.2

“Xpert HIV-1 Qual XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand with results in as little as 91 minutes. “said David Persing, M.D., Ph.D., EVP, Chief Medical and Scientific Officer at Cepheid.”…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]